Sep 30, 2026 · 7 min
Asian markets split between drug optimism and chip anxiety
Insilico Rises, Hygon Dips, AOU Gains
The episode shows how licensing and clinical progress are lifting Chinese pharmaceuticals even as supply constraints and healthcare costs weigh elsewhere.
- 1Chinese pharmaceutical shares rally on licensing activity, clinical developments, and an obesity-focused drug candidate.
- 2Chinese hardware and semiconductor stocks weaken as supply limits, production concerns, and Nvidia chip access cloud prospects.
- 3Taiwanese chipmakers benefit from U.S. trading strength and TSMC optimism, while India confronts steep oncology costs.
Don't miss
India’s top court describes steep oncology and cancer-treatment charges as “carnage,” linking market news to the social cost of healthcare inflation.
The brief
Asian markets are not moving as one bloc: Chinese pharmaceutical shares rally on licensing, clinical developments, and Insilico Medicine’s obesity-focused candidate while broader Chinese equities weaken.
GenScript, CS Pharma, and other pharmaceutical names benefit from drug-development momentum, contrasting with Chinese hardware and semiconductor weakness tied to supply and production concerns.
Uncertainty over access to older Nvidia chips adds pressure to Chinese technology stocks, underscoring how supply-chain limits can outweigh enthusiasm for the sector.
Taiwanese chipmakers gain from strong U.S. chip trading and optimism around TSMC, while glass-substrate technology points to a new battleground in complex chip packaging.
India’s top court criticizes steep oncology charges as “carnage,” placing drug and cancer-treatment costs within a broader effort to contain healthcare inflation.
What was said on this episode
14 statements · 10 positive · 3 negative · 1 mixed
China’s pharmaceutical sector is outperforming broader Chinese equities.
“the pharmaceutical sector is really starting to stand out”
Listen at 0:50
Insilico shares rose about 8% after releasing an obesity-targeting molecule.
“Insilico, which is an AI-driven drugs developer, that's up around 8% as it releases a molecule to perhaps tackle obesity”
Listen at 1:11
The HS Bio Index is materially outperforming a flat broader market.
“HS Bio materially outperforming a market that's flat”
Listen at 1:30
Chinese hardware makers lag the American supply chain and cannot produce at expected scale.
“they are still very far behind the American supply chain and more importantly, not capable of producing on the kind of scale that was expected”
Listen at 1:49
China appears prepared to allow imports of some older Nvidia chips.
“the Chinese government looks prepared to accept some of Nvidia's older chips into the country”
Listen at 2:02
The Nvidia-chip headline accelerated declines in Chinese hardware stocks.
“there's been a bit of a sharper move to the downside accelerating this flow”
Listen at 2:13
TSMC’s ADR premium is near the top of its range at about 20%.
“TSMC ADR premium is back in the near the top end of the range, near 20%”
Listen at 2:42
TSMC is a major buyer of components from Taiwanese suppliers.
“TSMC is a huge buyer of components from everyone else in Taiwan”
Listen at 2:50
Chip packaging is shifting from plastic to glass as chips become more complex.
“people are moving on to packaging them in glass”
Listen at 3:09
AUO and Innolux shares are trading near their daily limits.
“AUO is almost limit up and Innolux is up almost limit up as well”
Listen at 3:19
AUO and Innolux shares surged after glass-substrate technology was unveiled.
“These stocks have been on an absolute tear ever since this glass substrate technology was unveiled.”
Listen at 3:23
Indian hospital stocks declined between 5% and 11%.
“You're seeing losses of anywhere from 5% to 11% in the hospital sector”
Listen at 4:19
The Indian drug landscape may continue changing, affecting the hospital sector.
“keep an eye out on this sector for continued changes in the Indian drug landscape”
Listen at 4:31
Indian drugmakers benefit from strong domestic demand for healthcare.
“Indian drugmakers, on the other hand, are benefiting from very strong domestic demand”
Listen at 4:38
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.
Nathan Hager
Anthony Stevens
Asia
Bloomberg L.P.Listen to the full episode and explore every guest, topic, and moment on PodLume.